

# Contents

<b>Chapter 1 Etiology and Pathogenesis of Parkinson's Disease</b>	<b>1</b>
<i>Briana R. de Miranda and J. Timothy Greenamyre</i>	
1.1 Introduction	1
1.2 Clinical Manifestations of Parkinson's Disease	2
1.3 Neuropathology	3
1.3.1 Selective Vulnerability of the Nigrostriatal Dopamine Neuron	4
1.3.2 Mitochondrial Dysfunction in PD	6
1.3.3 Oxidative Stress	8
1.3.4 Dopamine Metabolism	9
1.3.5 Neuroinflammation	11
1.4 Genetics of Parkinson's Disease	12
1.5 Environmental Exposures and the Risk of Parkinson's Disease	13
1.5.1 Pesticides	13
1.5.2 Metals	14
1.5.3 Pathogens	14
1.6 Gene–Environment Interaction	15
1.7 Conclusions	16
Acknowledgements	16
References	16

---

Issues in Toxicology No. 34

Oxidative Stress and Redox Signalling in Parkinson's Disease

Edited by Rodrigo Franco, Jonathan A. Doorn and Jean-Christophe Rochet

© The Royal Society of Chemistry 2017

Published by the Royal Society of Chemistry, [www.rsc.org](http://www.rsc.org)

<b>Chapter 2</b>	<b>Oxidative Stress and Redox Signalling in the Parkinson's Disease Brain</b>	<b>27</b>
	<i>Pablo Hernandez-Franco, Annandurai Anandhan, Rachel M. Foguth and Rodrigo Franco</i>	
2.1	Introduction	27
2.2	Oxidative Stress and Antioxidant Systems	28
2.2.1	Reactive Oxygen and Nitrogen Species: Sources	28
2.2.2	Antioxidant Systems	31
2.2.3	Oxidative Damage to Biomolecules	33
2.3	What Makes the Dopaminergic Neurons in the SNpc Vulnerable?	37
2.3.1	Cellular Organization of the SNpc	37
2.3.2	Redox Basis of the Vulnerability of SNpc DAergic Neurons	39
2.4	Conclusions and Perspectives	44
	Acknowledgements	44
	References	44
<b>Chapter 3</b>	<b>Mitochondrial Dysfunction in Parkinson's Disease</b>	<b>61</b>
	<i>Manisha Patel and Pallavi Bhuyan McElroy</i>	
3.1	Reactive Oxygen Species (ROS)	61
3.1.1	Mitochondria and ROS Production	62
3.2	Parkinson's Disease	63
3.3	Mitochondrial Dysfunction in PD	64
3.3.1	ETC Complex Deficiency in PD	65
3.3.2	Altered Mitochondrial Morphology	67
3.3.3	Mitochondrial Ca <sup>2+</sup> Buffering in PD	67
3.3.4	PD-Related Genes and Mitochondrial Dysfunction	68
3.4	Mitochondrial Dysfunction in Toxicant-Induced PD	69
3.4.1	6-OHDA and MPTP: Classic Toxicant Models	70
3.4.2	Rotenone: A Case for Complex I Inhibition	73
3.4.3	Paraquat: Redox Cycling Agent	75
3.4.4	Maneb: A Role of Complex III in PD Pathogenesis	81
3.4.5	Other Environmental Toxins	82
3.5	Concluding Remarks	83
	References	85

<b>Chapter 4 Dopamine Metabolism and the Generation of a Reactive Aldehyde</b>	<b>97</b>
<i>Josephine H. Schamp and Jonathan A. Doorn</i>	
4.1 The Life of Dopamine: Synthesis, Storage and Metabolism	97
4.2 3,4-Dihydroxyphenylacetaldehyde (DOPAL) and Biogenic Aldehydes Derived from Neurotransmitters	100
4.3 Generation of DOPAL and Biogenic Aldehydes at Aberrant Levels	101
4.3.1 Mechanisms for Elevation of DOPAL	101
4.3.2 Relevance of Altered Dopamine Metabolism/Trafficking to PD	102
4.4 Toxicity and Protein Reactivity of DOPAL and Biogenic Aldehydes	103
4.4.1 Mechanisms of Toxicity	104
4.4.2 Protein Reactivity and Targets	104
4.5 The Role of Biogenic Aldehydes in Disease	105
4.6 Summary	106
References	107
<b>Chapter 5 Dopamine Oxidation and Parkinson's Disease</b>	<b>116</b>
<i>Caitlyn W. Barrett, Meghan L. Bucher and Teresa G. Hastings</i>	
5.1 Oxidative Stress and Susceptibility of Dopaminergic Neurons in Parkinson's Disease	116
5.2 Dopamine Regulation and Metabolism	117
5.3 Pathological Dopamine Oxidation	118
5.3.1 Metabolism of Dopamine by Monoamine Oxidase	118
5.3.2 Oxidation of the Catechol Ring of Dopamine	119
5.3.3 Modification of Protein by Oxidized Dopamine	119
5.3.4 Mitochondrial Dysfunction and Dopamine Oxidation	122
5.4 The Role of Dopamine in Toxin-Induced Toxicity	124
5.5 Dopamine Toxicity	125
5.5.1 <i>In vitro</i> Exogenous Dopamine and L-DOPA Treatment	125
5.5.2 Exogenous Dopamine Administration <i>in vivo</i>	126
5.5.3 Dysregulation of Dopamine Handling <i>in vivo</i>	127
5.6 Dopamine and $\alpha$ -Synuclein	128
5.7 Dopamine Storage Disruption in PD	129
5.8 Summary and Conclusions	130
References	131

<b>Chapter 6</b>	<b>Glutathione and Thiol Redox Signalling in Parkinson's Disease</b>	<b>144</b>
	<i>Michelle Smeyne and Richard Jay Smeyne</i>	
6.1	Introduction	144
6.2	Glutathione	145
6.3	Thiol Redox Signalling and Thiol–Disulfide Exchange	146
6.4	Cellular Reductases	148
6.4.1	Thioredoxins	149
6.4.2	Glutaredoxins	150
6.4.3	Peroxiredoxins	151
6.5	Glutathione Synthesis in the Brain	152
6.6	Glutathione and Models of Oxidative Stress in Dopaminergic Neurons	154
6.7	Glutathione Conjugating Enzymes	155
6.7.1	Glutathione Peroxidase	155
6.7.2	Glutathione S-Transferases	156
6.8	GSH and Transport in the Brain: Multidrug Resistance Proteins (MDRP) and the Blood–Brain Barrier (BBB)	158
6.9	Parkinson's Disease Genetic Models and Redox Signalling	159
6.9.1	Glutathione-S-Transferase	159
6.9.2	DJ-1	160
6.9.3	PTEN-Induced Putative Kinase 1 (PINK1)	160
6.9.4	Parkin	161
6.10	Free Radicals as Messengers to Modulate Transcription Factors: Effects on Thiol Redox Regulation	161
6.11	Conclusions	162
	References	162
<b>Chapter 7</b>	<b>Neuroinflammation and Oxidative Stress in Models of Parkinson's Disease and Protein-Misfolding Disorders</b>	<b>184</b>
	<i>Ronald B. Tjalkens, Karin M. Streifel and Julie A. Moreno</i>	
7.1	Introduction	184
7.2	Molecular Pathways Regulating Neuroinflammation in Glial Cells	185
7.2.1	Regulation of Inflammatory Genes in Glial Cells by NF- $\kappa$ B	185
7.2.2	Nuclear Regulation of NF- $\kappa$ B Function in Glial Cells	186

7.3 Neurotoxic Models of Parkinson's Disease: Reactive Oxygen Species and Neuroinflammatory Mechanisms	188
7.3.1 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)	188
7.3.2 6-Hydroxydopamine (6-OHDA)	191
7.3.3 Lipopolysaccharide (LPS)	192
7.4 Neuroinflammation and Protein Aggregation in PD and Protein-Misfolding Disorders	193
7.4.1 Neuroinflammation in Protein-Misfolding Disorders	194
7.4.2 Oxidative Stress in Protein-Misfolding Disorders	195
7.4.3 Unfolded Protein Response in Protein-Misfolding Disorders	196
7.5 Conclusions	197
References	198
<b>Chapter 8 Redox Signalling in Dopaminergic Cell Death and Survival</b>	<b>210</b>
<i>Ajit Ray, Aditi Verma and Vijayalakshmi Ravindranath</i>	
8.1 Neuronal Degeneration in Parkinson's Disease	210
8.1.1 Relatively Selective Dopaminergic Degeneration	211
8.1.2 Sources of Oxidative Stress and Selective Vulnerability	211
8.1.3 Increased Oxidative Stress and Selective Cell Death	216
8.2 Redox Signalling and Cell Survival/Death	217
8.3 Redox Regulation of DAergic Cell-Survival Pathways	217
8.3.1 Akt Structure and Function	217
8.3.2 Evidence of Akt1 Involvement in PD	219
8.3.3 Redox Regulation of Akt1 Activity	220
8.4 Redox Regulation of DAergic Cell-Death Pathways	223
8.4.1 Redox Regulation of MAP3K-ASK1	223
8.4.2 MAPKs – p38 and JNK	231
8.5 Conclusions	233
Acknowledgements	234
References	235
<b>Chapter 9 Iron Metabolism in Parkinson's Disease</b>	<b>255</b>
<i>Guofen Gao, Lin-Hao You and Yan-Zhong Chang</i>	
9.1 Brain Iron Homeostasis	255
9.1.1 Brain Iron Transport and Distribution	256
9.1.2 Regulation of Brain Iron Homeostasis	257

9.2	Iron Metabolism and Parkinson's Disease	258
9.2.1	Symptoms of Parkinson's Disease	259
9.2.2	Iron Accumulation Accelerates the Symptomatology of Parkinson's Disease	259
9.2.3	Mechanism of Iron Accumulation in the <i>Substantia Nigra</i> of Parkinson's Disease Brains	260
9.2.4	Iron and the Aggregation of $\alpha$ -Synuclein	264
9.2.5	Iron, ROS and Apoptosis of Dopaminergic Neurons in the <i>Substantia Nigra</i> of Parkinson's Disease	264
9.3	Iron-Related Therapeutic Approaches for PD	266
9.4	Conclusions	268
	References	268
<b>Chapter 10</b>	<b>Protein Oxidation, Quality-Control Mechanisms and Parkinson's Disease</b>	<b>277</b>
	<i>Pablo Hernandez-Franco, Annadurai Anandhan and Rodrigo Franco</i>	
10.1	Introduction	277
10.2	Misfolded Protein Aggregation and Accumulation in PD	278
10.2.1	$\alpha$ -Synuclein: Mutations and Misfolding	279
10.3	Protein Quality-Control Mechanisms in PD	283
10.3.1	Protein Synthesis	283
10.3.2	Protein Folding, Unfolding and Disaggregation by Chaperones	284
10.3.3	Protein Degradation Pathways	287
10.3.4	Protein Quality Control in Organelles	293
10.4	Conclusions and Perspectives	297
	Acknowledgements	297
	References	297
<b>Chapter 11</b>	<b>At the Intersection Between Mitochondrial Dysfunction and Lysosomal Autophagy: Role of PD-Related Neurotoxins and Gene Products</b>	<b>325</b>
	<i>Josephat M. Asiago, Trevor B. Doyle, Vartika Mishra, Aurélie de Rus Jacquet and Jean-Christophe Rochet</i>	
11.1	Introduction	325
11.2	Neuropathological Evidence for Mitochondrial Deficits and Autophagic Impairment in PD	327
11.2.1	Evidence of Mitochondrial Deficits in Postmortem PD Brains	327
11.2.2	Evidence of Autophagic Impairment in Postmortem PD Brains	328

11.3	Toxicological Evidence for Mitochondrial Deficits and Autophagic Impairment in PD	330
11.3.1	Rotenone	330
11.3.2	PQ and Maneb	332
11.3.3	MPTP or MPP <sup>+</sup>	334
11.3.4	6-OHDA	336
11.4	Genetic Evidence for Mitochondrial Deficits and Autophagic Impairment in PD	337
11.4.1	aSyn	338
11.4.2	Parkin/PINK1	340
11.4.3	DJ-1	344
11.4.4	ATP13A2	347
11.5	Interrelationships Between Autophagic Impairment and Mitochondrial Dysfunction	349
11.6	Summary and Future Directions	350
	References	352
<b>Chapter 12</b>	<b>Genes, Aging, and Parkinson's Disease</b>	<b>389</b>
	<i>Chiara Milanese and Pier G. Mastroberardino</i>	
12.1	Introduction	389
12.1.1	Do Genes Influence Lifespan?	390
12.1.2	Which Genes Influence Lifespan?	391
12.2	Apolipoprotein E	393
12.2.1	LDL Receptors	394
12.2.2	Effects of Polymorphisms on APOE Function	395
12.2.3	APOE and Parkinson's Disease	396
12.2.4	APOE Oxidative Stress	397
12.3	FOXO3A and FOXO Family	397
12.3.1	FOXO3A Biological Functions	398
12.3.2	FOXO3A and Protein Homeostasis	400
12.3.3	FOXO3A and Parkinson's Disease	401
12.4	Role of Other Genes Emerged from Animal Studies in Aging	401
12.4.1	Are Aging-Modifying Genes Discovered in Laboratory Animals Relevant for PD?	404
	References	405
<b>Chapter 13</b>	<b>Biomarkers of Oxidative Stress in Parkinson's Disease</b>	<b>423</b>
	<i>Emilio Fernández</i>	
13.1	Biomarkers	423
13.2	Oxidative Stress	424
13.3	Candidate Biomarkers for ROS-Induced Stress	426
13.3.1	Halogenation	427
13.3.2	Methionine Oxidation	429
13.3.3	Glycation and Carbonylation	429

13.4 Candidate Biomarkers for RNS-Induced Stress	429
13.4.1 Nitration	430
13.4.2 <i>S</i> -nitros(yl)ation	434
13.5 Conclusions	435
References	436
<b>Chapter 14 Dietary Anti-, Pro-Oxidants in the Etiology of Parkinson's Disease</b>	<b>447</b>
<i>Zeynep Sena Agim and Jason R. Cannon</i>	
14.1 Introduction	447
14.2 Heterocyclic Amines	448
14.3 Polyphenolic Compounds	450
14.3.1 Flavonoids	450
14.3.2 Non-Flavonoids	462
14.4 Vitamins	467
14.4.1 Vitamin A	467
14.4.2 Vitamin B	469
14.4.3 Vitamin C	470
14.4.4 Vitamin D	471
14.4.5 Vitamin E	473
14.5 Summary	474
References	475
<b>Subject Index</b>	<b>505</b>